15-valent pneumococcal conjugate vaccine

Merck's CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine, has demonstrated robust immune responses in adults, particularly those with increased risk factors for pneumococcal disease.

The CDC recommends the 21-valent pneumococcal conjugate vaccine (PCV21) for adults, particularly those at higher risk of pneumococcal disease, to broaden protection against invasive strains.

The FDA has approved Merck's CAPVAXIVE, a novel 21-valent pneumococcal conjugate vaccine specifically designed to protect adults against serotypes causing the majority of invasive pneumococcal disease.